Important note
This AI stock analysis for Regeneron is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Regeneron - AI Stock Analysis
Analysis generated January 27, 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company focused on the discovery, development, manufacturing, and commercialization of pharmaceuticals. Regeneron is well-known for its innovative approach to drug development, leveraging genetics to identify new and effective therapies for various diseases. The company has a robust pipeline of drugs and collaborative relationships with other industry giants.
Fundamental Analysis
Regeneron reported revenue of $3.72 billion for the last quarter, which signifies an increase of 4.89% compared to the previous quarter. This is a positive indicator of quarterly growth. On a year-over-year basis, revenue has grown by 11.24%, highlighting sustained growth over an extended period.
Net income for the last quarter was $1.34 billion. However, this figure is down by 6.40% from the previous quarter, which could be a concern. On the brighter side, year-over-year net income saw an increase of 33.02%, indicating stronger profitability compared to the same period last year.
EBITDA for the last quarter was $1.63 billion, marking a significant increase of 34.12% from the previous quarter and a robust year-over-year increase of 46.58%. This shows strong operational performance and cash flow generation.
The current P/E ratio stands at 16.72, which is considered within a normal range, suggesting that the stock is neither overvalued nor undervalued.
Technical Analysis
Regeneron’s stock price is currently at $685.09, reflecting a decrease of 3.83% compared to a month ago. Over the past year, the stock price has dropped by 27.12%, indicating potential long-term concerns.
Despite the recent decline, the trend remains bullish. The current SMA10 is 681.97, slightly higher than the previous SMA10 of 681.62, suggesting a potential upward price movement.
The RSI is 57.4, indicating a neutral condition. This means the stock is neither overbought nor oversold, and there are no immediate signals for a reversal in trend.
Alternative Data Analysis
As for job postings and employee sentiment, Regeneron has 332 open positions, a decrease of 41% in recent months. This might indicate cost-cutting measures, which is not an encouraging sign for growth.
From a customer acquisition perspective, Regeneron’s website has seen an estimated 230,000 visitors, down by 36% in the past few months. This decrease in web traffic could be a red flag for customer interest and brand visibility.
Regarding customer engagement, Regeneron counts 14,000 Instagram followers, with a 3% increase recently, showing positive interest. However, their 33,000 Twitter followers have decreased by 1%, indicating a decline in engagement.
Lastly, AltIndex’s AI score for Regeneron stands at 38, which is a sell signal based on a blend of fundamental, technical, and alternative data.
Conclusion and Recommendation
Regeneron shows strong fundamental performance with incremental revenue growth and a solid EBITDA increase, although a slight quarter-over-quarter dip in net income warrants attention. On the technical front, the stock appears to be in a bullish trend, but the declines in stock price raise concerns.
The alternative data suggests mixed signals, with reductions in job postings and web traffic pointing to potential headwinds, but slight improvements in some customer engagement metrics.
Given these mixed signals, a cautious approach is recommended. While Regeneron remains fundamentally strong, the concerns raised by alternative data and recent stock performance suggest that potential investors should keep a close eye on upcoming quarterly results and market conditions before making substantial investments.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
